Neurotech Bolsters Cash Position with $2.44 Million R&D Tax Incentive Refund

Neurotech International Ltd. ( (AU:NTI) ) just unveiled an update.

Neurotech International Ltd. has announced receiving a $2.44 million R&D tax incentive refund from the Australian Federal Government. This financial boost strengthens the company’s cash position, supporting its ongoing clinical trials and preparations for regulatory submissions to the Australian Therapeutic Goods Administration and US Food and Drug Administration in fiscal year 2025. The refund underscores Neurotech’s commitment to advancing its research in pediatric neurological disorders, potentially enhancing its industry positioning and stakeholder confidence.

More about Neurotech International Ltd.

Neurotech International Limited (ASX: NTI) is a clinical-stage biopharmaceutical development company specializing in pediatric neurological disorders. The company has completed a Phase I/II clinical trial in Autism Spectrum Disorder (ASD) with promising safety and efficacy results and is engaged in further trials for ASD, PANDAS/PANS, and Rett Syndrome. Additionally, Neurotech is commercializing Mente, a home therapy for autistic children.

YTD Price Performance: -20.0%

Average Trading Volume: 685,709

Technical Sentiment Consensus Rating: Buy

Current Market Cap: A$50.02M

See more data about NTI stock on TipRanks’ Stock Analysis page.